Birmingham Quality POCT Suite
[Birmingham Quality POCT Suite]
EPTIS Ringversuch Nr. 1615706 | Letze Änderung 2026-09-24 | URL: https://www.eptis.bam.de/pts1615706 https://www.eptis.bam.de/pts1615706
| Name des Anbieters | ||||||||||||||||||||||||||||
| Name des Anbieters | Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||||||||
| Sprache(n) | English | |||||||||||||||||||||||||||
| Anmerkungen | This suite allows a range of analytes and a range of frequency options tailored to your specific needs. Operating as a Hub-and-Spoke, not only do individual end users receive an easy to understand report, but the Hub coordinator receives a range of reports and spreadsheets for them to efficiently run their own service in the way they want. Provides EQA coverage for a range of analytes for which Point of Care Testing is commonly performed in a variety of settings, including hospital settings and community settings such as GP surgeries, pharmacies and gyms. Analytes include HbA1c and Lipids which are part of the NHS Health Checks programme for Diabetes and Cardiovascular Risk assessment, and Creatinine. HbA1c is also often performed as POC test in Diabetes clinics and by Diabetic home care teams. Creatinine is often analysed by POC devices to assess renal function in the clinic setting, especially in radiology (before contrast administration), and oncology (before chemotherapy treatment). Material is Whole Blood for all schemes, as patient testing is often performed on finger prick capillary samples. The scheme also allows hub coordinators to monitor performance of devices across all locations. | |||||||||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||||||||
| Zielgruppe des Ringversuchs | Clinical Chemistry Public & Private Labs | |||||||||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | ISO/IEC 17043:2023 | |||||||||||||||||||||||||||
| Weitere Ziele | Post market surveillance of testing methods | |||||||||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043:2023 |
|||||||||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||||||||
| Teilnahmegebühr | Contact provider for current fee, which depends on location and extent of service required. | |||||||||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Various) | |||||||||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2020 | |||||||||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||||||||
|
Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Medical Centre P O Box 3909 B15 2SQ Birmingham United Kingdom Telefon: +44 121 414 7300 Fax: Web: https://www.birminghamquality.org.uk https://www.birminghamquality.org.uk |
Birmingham Quality
Telefon: +44 121 414 7300 Fax: E-Mail: birminghamquality@uhb.nhs.uk birminghamquality@uhb.nhs.uk |
|||||||||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.